



Registered company number - 04697468

KENT CANCER TRUST  
(A COMPANY LIMITED BY GUARANTEE)

TRUSTEES' ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024

# KENT CANCER TRUST

## CONTENTS

---

|                                   | <b>Pages</b> |
|-----------------------------------|--------------|
| Trustees' Annual Report           | 1 - 3        |
| Independent Examiner's Report     | 4            |
| Statement of Financial Activities | 5            |
| Balance Sheet                     | 6            |
| Notes to the Financial Statements | 7 - 10       |

**TRUSTEES' ANNUAL REPORT  
FOR THE YEAR ENDED 31 MARCH 2024**

---

The Trustees, who are also Directors for the purposes of company law, have pleasure in presenting their report and the unaudited financial statements of the Charity for the year ended 31 March 2024 which are also prepared to meet the requirements for a directors' report and accounts for Companies Act purposes.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective January 2019).

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Charity Registration Number**  
1105730

**Company Registration Number**  
04697468

**Registered Office**

The Marlowe Innovation Centre  
Marlowe Way  
Ramsgate  
Kent  
CT12 6FA

**Trustees/Directors**

|                  |           |
|------------------|-----------|
| Dr Mary Buchanan |           |
| Mr Tim Bentley   | Treasurer |
| Dr Kate Winstone | Chair     |
| Mr K Jackson     |           |
| Mrs Mary B Tripp |           |

**Independent Examiner**

Mr S J Wren FCCA  
Accountancy Matters (Kent) Limited  
The Marlowe Innovation Centre  
Marlowe Way  
Ramsgate  
Kent  
CT12 6FA

**TRUSTEES' ANNUAL REPORT  
FOR THE YEAR ENDED 31 MARCH 2024**

---

**STRUCTURE, GOVERNANCE AND MANAGEMENT****Governing document**

The organisation is a charitable company limited by guarantee. It was incorporated on 13 March 2003 and registered as a charity on 3 September 2004.

The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

**Recruitment and appointment of trustees**

Under the requirements of the Memorandum and Articles of Association, the trustees are elected to serve for a period of three years after which time they must be re-elected at the next Annual General Meeting.

**Organisational structure**

The Board was chaired by Dr Katherine Winstone during the year to 31 March 2024, assisted by Mr Timothy Bentley as Secretary and Treasurer. Regular contact between the Board members involved face to face, telephone and Zoom meetings.

**Risk management**

The trustees carry out an annual review of the risks which the charity may face and have established systems and procedures designed to minimise any potential impact on the charity should any risks materialise.

**OBJECTIVES AND ACTIVITIES**

The company's objects and principal activities are to relieve the suffering of cancer patients and improve the provision of cancer care within the Kent area particularly but not exclusively by the following:

- \* The promotion of the development and training of cancer clinicians, medical staff and students in the disease
- \* The promotion of research into the cause and treatment of cancer and the dissemination of the results with a view to the development of new treatments and diagnostic aids
- \* The advancement of education and awareness of the public in the cause and treatment of cancer.
- \* Such other assistance as the trustees shall deem necessary.

**Achievements, Performance and Future Plans**

During the year, Kent Cancer Trust has raised sufficient funds to enable a small video to be produced to encourage post GCSE students to consider a career in biosciences, thus meeting the objective to advance the awareness of young people in the possibility of working on improvements in the treatment of cancer

Work on the programme to reduce the risk of harmful micro-organisms growing in PEG feeding tubes has continued to a point where Kent Cancer Trust's funding has demonstrated the possibilities of improvement in this area, thus enabling the University of Kent to obtain a significant increase in the funding available for this project.

Kent Cancer Trust has taken part in discussions on cancer treatments at the University of Kent as well as at a major meeting organised by the British Association for Cancer Research in July 2024 that provided a good networking opportunity to investigate potential new funding possibilities

Note 3 to the accounts shows the wide range of projects that have been supported by Kent Cancer Trust since its formation.

In October 2023 a Ball was held at Nurstead Court, Meopham that generated net income of nearly £17,000. After a long period of minimal fundraising as a result of the restrictions imposed due to Covid-19, it was good to be able to start to generate funds again

**TRUSTEES' ANNUAL REPORT  
FOR THE YEAR ENDED 31 MARCH 2024**

---

**FINANCIAL REVIEW****Financial position**

The accounts set out on pages 5 to 10 show the income and expenditure and reserves at the year end.

**Reserves Policy and going concern**

No formal reserves policy has been adopted but the intention is that spending commitments will be fully covered by available funds before they are undertaken.

**Investment Powers**

The trustees and directors have the power to invest monies of the organisation in such investments as may be thought fit.

**PUBLIC BENEFIT**

Reference was made in the report for 2023 about the help that has been provided to MSc and PhD students who have worked on new treatment protocols to reduce biofilm growth when silicone prostheses are used following treatment for throat cancer. That particular project is part of ongoing work within an overall candida management pathway project, thus providing ongoing public benefit.

Signed on behalf of the Board of Trustees by :



Timothy Bentley - Trustee

Date : 4th September 2024



**KENT CANCER TRUST**

---

I report to the Charity trustees on my examination of the accounts of the company for the year ended 31 March 2024 which are set out on pages 5 to 10.

**Responsibilities and basis of report**

As the Charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your Charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

- 1     accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
- 2     the accounts do not accord with those records; or
- 3     the accounts do not comply with the accounting requirements of section 386 of the 2006 Act other than any requirements that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
- 4     the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

**S J Wren FCCA**  
**Accountancy Matters (Kent) Limited**  
**Chartered Certified Accountants**  
**The Marlowe Innovation Centre**  
**Marlowe Way**  
**Ramsgate**  
**Kent CT12 6FA**

Date :

**STATEMENT OF FINANCIAL ACTIVITIES**  
**(incorporating an Income and Expenditure Account)**  
**FOR THE YEAR ENDED 31 MARCH 2024**

|   | Notes | Unrestricted<br>funds<br>£ | Restricted<br>funds<br>£ | Total<br>funds<br>2024<br>£ | Total<br>funds<br>2023<br>£ |
|---|-------|----------------------------|--------------------------|-----------------------------|-----------------------------|
| <b>INCOME</b>   |       |                            |                          |                             |                             |
| Donations and grants  | 2     | 5,392                      | -                        | 5,392                       | 10,417                      |
| Charitable activities   |       | -                          | -                        | -                           | -                           |
| Other trading activities - Ball                                   |       | 23,637                     | -                        | 23,637                      | -                           |
| Investment income   |       | -                          | -                        | -                           | -                           |
| <b>TOTAL INCOME</b>   |       | <b>29,029</b>              | <b>-</b>                 | <b>29,029</b>               | <b>10,417</b>               |
| <b>EXPENDITURE</b>  |       |                            |                          |                             |                             |
| Cost of raising funds   |       | 7,723                      | -                        | 7,723                       | 1,327                       |
| Charitable activities   |       | 2,481                      | -                        | 2,481                       | 10,764                      |
| <b>TOTAL EXPENDITURE</b>  | 3     | <b>10,204</b>              | <b>-</b>                 | <b>10,204</b>               | <b>12,091</b>               |
| <b>NET (EXPENDITURE)/INCOME FOR THE YEAR<br/>BEFORE TRANSFERS</b> | 6     | <b>18,825</b>              | <b>-</b>                 | <b>18,825</b>               | <b>(1,674)</b>              |
| Transfers between funds   |       | -                          | -                        | -                           | -                           |
| <b>NET MOVEMENT IN FUNDS FOR THE YEAR</b>                         |       | <b>18,825</b>              | <b>-</b>                 | <b>18,825</b>               | <b>(1,674)</b>              |
| Balance as at 1 April 2023  |       | 9,586                      | -                        | 9,586                       | 11,260                      |
| <b>BALANCE AS AT 31 MARCH 2024</b>                                |       | <b>28,411</b>              | <b>-</b>                 | <b>28,411</b>               | <b>9,586</b>                |

**BALANCE SHEET**  
**AS AT 31 MARCH 2024**

|  | Notes | 2024<br>£     | 2023<br>£    |
|--|-------|---------------|--------------|
| <b>FIXED ASSETS</b>                            |       |               |              |
| Tangible assets                                |       | -             | -            |
| <b>CURRENT ASSETS</b>                          |       |               |              |
| Debtors and prepayments                        | 6     | 231           | 351          |
| Cash at bank and in hand                       |       | <u>28,745</u> | <u>9,782</u> |
|  |       | 28,976        | 10,133       |
| <b>CURRENT LIABILITIES</b>                     |       |               |              |
| Creditors: amounts falling due within one year | 7     | <u>565</u>    | <u>547</u>   |
|  |       | 28,411        | 9,586        |
| <b>NET ASSETS</b>                              |       |               |              |
|  | 8     | <u>28,411</u> | <u>9,586</u> |
| Represented by:                                |       |               |              |
| <b>FUNDS OF THE CHARITY</b>                    |       |               |              |
| Unrestricted general fund                      | 9     | 28,411        | 9,586        |
| Designated funds                               | 9     | -             | -            |
| Restricted funds                               | 9     | <u>-</u>      | <u>-</u>     |
| <b>TOTAL FUNDS</b>                             |       | <u>28,411</u> | <u>9,586</u> |

For the financial year ended 31 March 2024 the company was entitled to exemption from audit under s.477 Companies Act 2006 and no members have deposited a notice under s.476 requiring an audit.

The Directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with s.386 of the Act for preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies and in accordance with the Charities SORP FRS 102.

Approved and signed for issue by the Trustees on

4th September 2024

Kate Winstone - Chair



Timothy Bentley - Treasurer



Company registration number - 04697468



**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

---

**1 ACCOUNTING POLICIES****a) Basis of accounting**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities : Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019) - (Charities SORP (FRS102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Companies Act 2006.

Kent Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

**b) Preparation of the accounts on a going concern basis**

The accounts have been prepared on a going concern basis as Kent Cancer Trust has an established rule that it will not fund any research work until the full cost of that funding has been raised before agreeing to commit funds to any proposal. This ensures that the research team has full confidence that it can rely on funds being available to meet pre-agreed commitments.

**c) Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**d) Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount can be measured reliably. All expenditure is accounted for on an accruals basis and includes VAT where applicable. Expenditure has been included under expense categories that aggregate all costs for allocation to activities.

Charitable expenditure - comprises those costs incurred by the charity in the delivery of its activities and services for beneficiaries. It includes both those costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them, including governance costs (costs associated with meeting the constitutional and statutory requirements of the charity and includes the Independent Examiners fee).

**e) Significant judgements and estimates**

No significant judgements or estimates have had to be made by the Trustees in preparing these financial statements.

**f) Fund accounting**

Unrestricted funds are grants, donations and other incoming resources receivable by the Charity without further specified purpose and are available as general funds.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim of each restricted fund is set out in the notes to the financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

| <b>2 DONATIONS AND GRANTS</b>                               | <b>Unrestricted funds</b> | <b>Restricted funds</b> | <b>2024 Total funds</b> | <b>2023 Total funds</b> |
|---|---------------------------|-------------------------|-------------------------|-------------------------|
|   | <b>£</b>                  | <b>£</b>                | <b>£</b>                | <b>£</b>                |
| Donations   | 5,161                     | -                       | 5,161                   | 10,066                  |
| Gift Aid  | 231                       | -                       | 231                     | 351                     |
|   | 5,392                     | -                       | 5,392                   | 10,417                  |
| <b>3 EXPENDITURE</b>  | <b>Unrestricted funds</b> | <b>Restricted funds</b> | <b>2024 Total funds</b> | <b>2023 Total funds</b> |
|   | <b>£</b>                  | <b>£</b>                | <b>£</b>                | <b>£</b>                |
| Cost of raising funds                                       |                           |                         |                         |                         |
| Ball costs  | 6,914                     |                         | 6,914                   | -                       |
| Website   | 318                       |                         | 318                     | 300                     |
| Just Giving   | 216                       |                         | 216                     | 216                     |
| Marketing and publicity                                     | 275                       | -                       | 275                     | 811                     |
|   | 7,723                     | -                       | 7,723                   | 1,327                   |
| Charitable activities costs                                 |                           |                         |                         |                         |
| Project costs (see below)                                   | 1,740                     | -                       | 1,740                   | 10,000                  |
| Support costs   |                           |                         |                         |                         |
| Insurance   | 176                       | -                       | 176                     | 217                     |
| Governance costs  |                           |                         |                         |                         |
| Companies House   | 13                        | -                       | 13                      | 13                      |
| Independent Examiner's fee                                  | 552                       | -                       | 552                     | 534                     |
|   | 2,481                     | -                       | 2,481                   | 10,764                  |
| <b>Total expenditure</b>                                    | <b>10,204</b>             | <b>-</b>                | <b>10,204</b>           | <b>12,091</b>           |
| <b>Project costs</b>  |                           |                         |                         |                         |
| PEG feeding tubes; Dr Gourlay                               |                           |                         | -                       | 10,000                  |
| Educational video   |                           |                         | 1,740                   | -                       |
|   |                           |                         | 1,740                   | 10,000                  |
| <b>Project costs from start of charity to 31 March 2024</b> |                           |                         |                         | <b>Total</b>            |
| Resistant Cancer Cell Line; Prof Michaelis                  |                           |                         |                         | 15,000                  |
| MSC student project; Prof Lloyd                             |                           |                         |                         | 24,600                  |
| Larynrectomy project; Dr Gourlay                            |                           |                         |                         | 36,292                  |
| Triple Negative Breast Screening; Prof Garrett              |                           |                         |                         | 16,802                  |
| Liquid nitrogen cyrostorage system                          |                           |                         |                         | 21,486                  |
| Public lecture costs  |                           |                         |                         | 1,077                   |
| Bowel screening promotion                                   |                           |                         |                         | 1,817                   |
| Antisense oligonucleotide project                           |                           |                         |                         | 73,763                  |
| Xcelligence system  |                           |                         |                         | 16,500                  |
| Effect of cancer treatment on male fertility                |                           |                         |                         | 8,000                   |
| Specific targeting of tumour cells                          |                           |                         |                         | 5,000                   |
| Venom study; Dr Trim  |                           |                         |                         | 12,000                  |
| Tracheostomy project; Dr Gourlay                            |                           |                         |                         | 32,823                  |
| PEG feeding tubes; Dr Gourlay                               |                           |                         |                         | 30,000                  |
| Bladder Cancer Prof Michaelis                               |                           |                         |                         | 5,000                   |
| Educational video   |                           |                         |                         | 1,740                   |
|   |                           |                         |                         | 301,900                 |

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

| <b>4 NET INCOME</b>                 | <b>2024</b> | <b>2023</b> |
|-------------------------------------|-------------|-------------|
|                                     | <b>£</b>    | <b>£</b>    |
| This is stated after charging:      |             |             |
| Depreciation                        | -           | -           |
| Independent Examiner's remuneration | 552         | 534         |
|                                     | <u>552</u>  | <u>534</u>  |

**5 INFORMATION REGARDING EMPLOYEES**

The average staff monthly head count was Nil (2023 - Nil).

No Trustees received remuneration during the year (2023 - £Nil) . No Trustee was paid expenses during the year (2023 - £Nil).

The total employee benefits (including employers national insurance) of the key management personnel of the Charity were £Nil (2023 - £Nil).

| <b>6 DEBTORS</b> | <b>2024</b> | <b>2023</b> |
|------------------|-------------|-------------|
|                  | <b>£</b>    | <b>£</b>    |
| Trade debtors    | -           | -           |
| Accrued income   | 231         | 351         |
|                  | <u>231</u>  | <u>351</u>  |

| <b>7 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b> | <b>2024</b> | <b>2023</b> |
|---|-------------|-------------|
|   | <b>£</b>    | <b>£</b>    |
| Trade creditors   | -           | -           |
| Accruals  | 565         | 547         |
|   | <u>565</u>  | <u>547</u>  |

**8 ANALYSIS OF NET ASSETS BETWEEN FUNDS**

|                                       | <b>General funds</b> | <b>Designated funds</b> | <b>Restricted funds</b> | <b>Total</b>  |
|---------------------------------------|----------------------|-------------------------|-------------------------|---------------|
|                                       | <b>£</b>             | <b>£</b>                | <b>£</b>                | <b>£</b>      |
| Fixed assets                          | -                    | -                       | -                       | -             |
| Current assets                        | 28,976               | -                       | -                       | 28,976        |
| Current liabilities                   | (565)                | -                       | -                       | (565)         |
| <b>Net assets as at 31 March 2024</b> | <u>28,411</u>        | <u>-</u>                | <u>-</u>                | <u>28,411</u> |

**ANALYSIS OF NET ASSETS BETWEEN FUNDS - PREVIOUS YEAR**

|                                       | <b>General funds</b> | <b>Designated funds</b> | <b>Restricted funds</b> | <b>Total</b> |
|---------------------------------------|----------------------|-------------------------|-------------------------|--------------|
|                                       | <b>£</b>             | <b>£</b>                | <b>£</b>                | <b>£</b>     |
| Fixed assets                          | -                    | -                       | -                       | -            |
| Current assets                        | 10,133               | -                       | -                       | 10,133       |
| Current liabilities                   | (547)                | -                       | -                       | (547)        |
| <b>Net assets as at 31 March 2023</b> | <u>9,586</u>         | <u>-</u>                | <u>-</u>                | <u>9,586</u> |



**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2024**

**9 MOVEMENT IN FUNDS**

|                            | As at<br>01 04 2023<br>£ | Income<br>£   | Expenditure<br>£ | Transfers<br>£ | As at<br>31 03 2024<br>£ |
|----------------------------|--------------------------|---------------|------------------|----------------|--------------------------|
| Restricted funds           | -                        | -             | -                | -              | -                        |
| Designated funds           | -                        | -             | -                | -              | -                        |
| Unrestricted general funds | 9,586                    | 29,029        | (10,204)         | -              | 28,411                   |
|                            | <u>9,586</u>             | <u>29,029</u> | <u>(10,204)</u>  | <u>-</u>       | <u>28,411</u>            |
| Total funds                | <u>9,586</u>             | <u>29,029</u> | <u>(10,204)</u>  | <u>-</u>       | <u>28,411</u>            |

**MOVEMENT IN FUNDS - PREVIOUS YEAR**

|                            | As at<br>01 04 2022<br>£ | Income<br>£   | Expenditure<br>£ | Transfers<br>£ | As at<br>31 03 2023<br>£ |
|----------------------------|--------------------------|---------------|------------------|----------------|--------------------------|
| Restricted funds           | -                        | -             | -                | -              | -                        |
| Designated funds           | -                        | -             | -                | -              | -                        |
| Unrestricted general funds | 11,260                   | 10,417        | (12,091)         | -              | 9,586                    |
|                            | <u>11,260</u>            | <u>10,417</u> | <u>(12,091)</u>  | <u>-</u>       | <u>9,586</u>             |
| Total funds                | <u>11,260</u>            | <u>10,417</u> | <u>(12,091)</u>  | <u>-</u>       | <u>9,586</u>             |

**10 MEMBERS LIABILITY**

The company is a company limited by guarantee. Every member of the Charity undertakes to contribute such amount as may be required, not exceeding £10, to the Charity's assets if it should be wound up while they are a member or within one year after they ceased to be a member, for the costs of winding up and for the adjustment of the rights of persons who have contributed to the Charity's assets.

**11 CORPORATION TAXATION**

The Charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

**12 RELATED PARTY TRANSACTIONS**

There were no transactions with related parties during the year under review or the preceding year.